Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31649403 | 0.80 | OPRL1 (0.41) | KDM4EOPRL1 | |
| SCHEMBL11947613 | 0.79 | OPRL1 (0.40) | KDM4EOPRL1 | |
| SCHEMBL14389977 | 0.79 | OPRL1 (0.40) | KDM4EOPRL1 | |
| SCHEMBL13291353 | 0.78 | KDM4E (0.56) | KDM4ELMNAHRH3ALDH1A1OPRL1 | |
| SCHEMBL14257980 | 0.78 | KDM4E (0.56) | KDM4ELMNAHRH3ALDH1A1OPRL1 | |
| SCHEMBL13224040 | 0.78 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL3459211 | 0.78 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL13224067 | 0.77 | OPRL1 (0.37) | KDM4EOPRL1 | |
| SCHEMBL12734546 | 0.77 | CYP2D6 (0.41) | OPRL1 | |
| SCHEMBL12734441 | 0.77 | CYP2D6 (0.41) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244852-B2 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBOTT LABORATORIES (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1601650-A2 | PROCESS FOR PREPARING 2-METHYLPYRROLIDINE AND SPECIFIC ENANTIOMERS THEREOF | Abbott Laboratories (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040260100-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004076388-A2 | PROCESS FOR PREPARING 2-METHYLPYRROLIDINE AND SPECIFIC ENANTIOMERS THEREOF | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040171845-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBOTT LABORATORIES | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171845-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | QDPR, PNMT, MTAP | KDM4E 239/4885LMNA 3055/4885HRH3 816/4885 |
| US-20040260100-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | QDPR, PNMT, MTAP | KDM4E 239/4885LMNA 3055/4885HRH3 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.